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The chromosomal passenger complex (CPC), composed of a kinase component, Aurora
B, the scaffolding subunit inner centromeric protein, Borealin, and Survivin, is a key
regulator of cell division. It controls multiple events, from chromosome condensation in
prophase to the final separation or abscission of the two daughter cells. The essential
functions of the CPC during metaphase, however, have always hindered an accurate
study of its role during cytokinesis. The recent development of small molecule inhibitors
against Aurora B and the use of elegant technologies such as chemical genetics have
offered new approaches to study the functions of the CPC at the end of cell division. Here,
we review the recent findings about the roles of the CPC in controlling the assembly of the
cleavage furrow, central spindle, and midbody. We will also discuss the crucial function of
this complex in controlling abscission timing in order to prevent abscission when lagging
chromatin is present at the cleavage site, thereby avoiding the formation of genetically
abnormal daughter cells. Finally, we offer our perspective on how to exploit the potential
therapeutic applications of inhibiting CPC activity during cytokinesis in cancer cells.
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INTRODUCTION
Faithful chromosome segregation during cell division is crucial for growth, development, and
reproduction in many organisms. Defects in this process have been associated with various genetic
diseases, including cancer. For example, many cancer cells present chromosomal instability (CIN),
which contributes to carcinogenesis by altering the balance of critical growth and death path-
ways and the overall expression of oncogenes and tumor suppressors. Thus, understanding the
mechanisms that control genome segregation during mitosis can reveal some of the processes that
promote genomic instability in cancer. Consistent with this, animal models have shown that failure
in controlling either chromosome segregation or the final separation of the two dividing cells –
cytokinesis – can cause CIN and carcinogenesis (1–4). Moreover, one of the hallmarks of cancer
is uncontrolled cell proliferation, and many cell division regulators are validated targets for the
isolation of novel chemotherapeutic drugs for the treatment of cancer pathologies. In particular,
mitotic serine/threonine kinases have become an intensively studied class of anticancer drug targets,
and inhibitors of mitotic kinases, such as Aurora and Polo-like kinases, are currently undergoing
clinical trials (5). A comprehensive knowledge of the function of these kinases is therefore crucial to
identify new pathways and biomarkers that could aid in the design of better-targeted and less toxic
anticancer therapies.
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The chromosomal passenger complex (CPC) is one of the
major regulators of cell division in all eukaryotes and is com-
posed of four subunits: the scaffolding component inner cen-
tromeric protein (INCENP), Borealin, Survivin, and Aurora B
kinase [reviewed by Carmena et al. (6)]. The name of the complex
reflects its dynamic distribution duringmitosis. It localizes to cen-
tromeres until chromosome segregation and then relocates to the
central spindle, an array of antiparallel and interdigitating micro-
tubules that forms between the separating sister chromatids after
anaphase onset (Figure 1). The translocation from centromeres
to the central spindle depends on the interaction of INCENP’s
coiled-coiled domain with microtubules and requires the kinesin
MKLP2/KIF20A (7, 8). Consistent with this localization, the CPC
controls various events throughout cell division, from chromo-
some condensation in prophase to the final separation or abscis-
sion of the two daughter cells. The best-known and most stud-
ied role of the CPC is undoubtedly the correction of improper
kinetochore–microtubule attachments in prometaphase, but there
is a growing evidence that the CPC plays important roles also
during cytokinesis. Cytokinesis is mediated by the constriction
of an actomyosin contractile ring at the equatorial cell cortex
that bisects the dividing cell. As mentioned earlier, after anaphase
onset, microtubules reassemble to form the central spindle, an
array of antiparallel microtubules that overlap at their plus ends
in a region called the spindle midzone (Figure 2). Central spindle
and astral microtubules cooperate to activate the small GTPase
RhoA at the equatorial cortex, which in turn triggers the assembly
and constriction of an actomyosin ring responsible for cleavage
furrow ingression. Furrow ingression progressively compacts the
central spindle to form an organelle known as the midbody,
which provides a platform important for the recruitment and
organization of many proteins that regulate the final abscission
of the two daughter cells (Figure 2). Here, we review recent
findings about the role of the CPC in controlling cleavage furrow
ingression, the formation and dynamics of the central spindle, the
architecture of the midbody, and abscission. Finally, we offer our
perspective on the possibility of exploiting the roles of the CPC in
cytokinesis for anticancer therapy.
THE CPC PROMOTES CENTRAL SPINDLE
AND MIDBODY FORMATION
Various microtubule-associated proteins cooperate to regulate the
assembly and dynamics of central spindle microtubules [reviewed
by Douglas and Mishima (9)]. The CPC has been shown to con-
trol the activities of at least two central spindle kinesin motors,
MKLP1/KIF23 and KIF4A (Figure 2).
MKLP1 is the motor component of the centralspindlin com-
plex, a heterotetramer composed of twoMKLP1 subunits and two
molecules of RacGAP1/MgcRacGAP/Cyk4 (10). Centralspindlin
is required for central spindle formation in many organisms, from
nematodes to humans (10–13), but is also known to performmany
other crucial roles during cytokinesis. For example, the RacGAP1
subunit interacts with and activates the RhoGEF Ect2, which in
turn promotes RhoA activation and contractile ring assembly and
constriction (14–17). RacGAP1 also associates with the plasma
membrane through its C1 domain, and this interaction provides a
crucial link between the midbody and the membrane, important
for the final abscission of the two daughter cells (18). Central-
spindlin activity is also essential for microtubule bundling (19)
and formation of the central spindle and midbody. To exert these
functions, centralspindlin complexes need to oligomerize, and
FIGURE 1 | The CPC shows dynamic localization during mitosis and cytokinesis. HeLa cells were fixed and stained to reveal Aurora B (red), tubulin (green),
and DNA (blue). The CPC (here represented by Aurora B) translocated from the mitotic chromosomes to the central spindle early in anaphase. In early telophase, the
CPC accumulated at the midbody arms. Scale bars: 10μm.
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FIGURE 2 | Aurora B substrates during cytokinesis. Schematic diagram illustrating the roles of the CPC at different stages of cytokinesis. The substrates of
Aurora B are indicated at the bottom. See text for details.
this clustering is promoted by Aurora B phosphorylation of the
serine 708 in the MKLP1 C-terminal tail. This phosphorylation
prevents the association of MKLP1 with 14-3-3 protein, which
inhibits centralspindlin clustering (20). Thus, Aurora B promotes
the assembly of the central spindle via phosphorylation of the
kinesin component of the centralspindlin complex.
The kinesin KIF4A and the microtubule-associated protein
PRC1 form another complex important for central spindle assem-
bly. PRC1 is able to cross-link and bundle microtubules and
is transported to the spindle midzone by KIF4A (21–25). The
formation of the PRC1/KIF4A complex is prevented by cyclin-
dependent kinase 1 (Cdk1) phosphorylation in metaphase (24),
but after anaphase onset, this interaction is instead promoted
through Aurora B phosphorylation of KIF4A (26). This phospho-
rylation also stimulates the microtubule-dependent ATPase activ-
ity of KIF4A, which suppresses microtubule dynamics and limits
the length of the central spindle (26). Quite interestingly, KIF4A
is also responsible for maintaining phosphatase PP2A-B56 at the
central spindle, thereby creating a spatially restricted negative
feedback loop counteracting Aurora B in cytokinesis (27).
We have recently found that the CPC directly interacts with
citron kinase (CIT-K), an important midbody protein that links a
network of contractile ring and central spindle proteins, includ-
ing actin, anillin, myosin, MKLP1, KIF14, and RhoA, in both
Drosophila and human cells (28–32). The CPC and CIT-K depend
on each other for proper localization to the midbody and Aurora
B phosphorylates CIT-K to control its localization and interaction
with central spindle partners (McKenzie et al., submitted). Thus,
a cross-regulatory mechanism between two important kinases
seems to regulate proper midbody architecture and successful
completion of cytokinesis.
New evidence also involved Aurora B in the regulation of Polo
kinase during cytokinesis in Drosophila. Polo kinase was the first
identified member of the evolutionary conserved family of Polo-
like kinases (Plk). All of the members of this family have essential
roles during cell division (33). Aurora B phosphorylates Polo on
its activation loop to promote its kinase activity in mitosis (34).
In cytokinesis, Aurora B-mediated phosphorylation of Polo is
responsible for its translocation from central spindlemicrotubules
to the midbody. Failure in this process induces cytokinesis defects
(35). Not much is known about Polo function at the end of
cytokinesis, but its localization is probably necessary to activate
substrates essential for abscission.
In conclusion, together these data indicate that the CPC orches-
trates the activity of various proteins to regulate the correct assem-
bly and size of both the central spindle and midbody (Figure 2).
IS THERE A ROLE FOR THE CPC IN
CLEAVAGE PLANE POSITIONING?
The CPC was found to accumulate at the spindle midzone and
equatorial cortex very rapidly after anaphase onset (Figure 1)
(36), leading to the proposal that this localization could reflect a
role for the CPC in positioning the division site and promoting
contractile ring assembly. In 2008, a study reported that CPC
translocation to the central spindle generates an Aurora B phos-
phorylation gradient that has its peak at the spindle midzone
(37). This Aurora B gradient has been suggested to determine
the position of the cleavage plane, but the molecular mechanisms
are still lacking. More recently, another group has reported that
Aurora B-mediated centralspindlin clustering is important to pro-
mote the interaction of the RacGAP1 with the plasma membrane
and proposed that this event could promote RhoA activation at
the cleavage furrow in both nematodes and human cells (38). In
conclusion, although these data point to a potential role forAurora
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B in furrow formation, further studies are needed to define the
molecules and mechanisms involved in this process.
THE CPC REGULATES
ABSCISSION TIMING
The CPC has been proposed to prevent abscission in the presence
of DNA at the cleavage site, thereby avoiding the formation of
genetically abnormal daughter cells (39). In this study, it was
reported that if lagging chromatin lingered at the cleavage site,
Aurora B remained active and stabilized the intercellular bridge.
The Aurora B target(s) in abscission, however, have remained elu-
sive until a few years ago when two studies simultaneously showed
that one of such targets is the Snf7 component of the endosomal
sorting complex required for transport III (ESCRT-III) (40, 41).
ESCRT proteins are evolutionarily conserved and best known for
catalyzing membrane fission events both in virus budding and in
the sorting of receptors into vesicles that bud off into the lumen of
the endosome, creating multivesicular bodies (MVBs) (42). The
ESCRT-III complex provides the core machinery that mediates
membrane deformation and fission events during these events
(43) as well as during abscission, which is topologically similar
to MVB biogenesis and virus budding (44). Consistent with this,
the ESCRT-III Snf7 components (known as CHMP4 proteins
in humans) form spiral filaments that appear to remodel and
constrict the membrane in order to create the abscission site (45).
The CPChas been proposed to regulate abscission timing through
direct interaction of the ESCRT-III Snf7 components both in
Drosophila and humans (40, 41). In human cells, Borealin directly
interacts with all three CHMP4 proteins, CHMP4A, CHMP4B,
and CHMP4C, and Aurora B phosphorylates the terminal tail of
CHMP4C. Two different models have been proposed to explain
the regulation of CHMP4 proteins by the CPC. Carlton et al.
(41) proposed that Aurora B phosphorylation promotes CHMP4C
translocation to the midbody ring, where this ESCRT-III com-
ponent inhibits abscission. By contrast, we proposed that CPC
controls abscission through inhibition of CHMP4 polymerization
and membrane association using two concurrent mechanisms:
interaction of its Borealin component with all three CHMP4
proteins and phosphorylation of CHMP4C by Aurora B (40).
These two concomitant events could preclude the formation of
the ESCRT-III filaments essential for the formation of the con-
striction that physically separate the two daughter cells. In this
model, CHMP4 proteins could assemble into spiral filaments only
after CPC removal from themidbody. Overall, the CPC-mediated
regulation of ESCRT-III has been suggested to act as a surveillance
mechanism that prevents abscission in the presence of DNA at the
cleavage site (39–41) (Figure 2).
TARGETING CPC FUNCTIONS IN
CYTOKINESIS: AN ALTERNATIVE TO THE
USE OF AURORA B SMALL MOLECULE
INHIBITORS IN CANCER THERAPY?
Aurora kinases are overexpressed and amplified in many tumors,
and Aurora A, but not Aurora B, displays oncogenic properties
(46–48). However, polyploid cells overexpressing Aurora B can
induce tumor formation when injected in nude mice, indicating
that high levels of this kinase can be tumorigenic when coupled
with cytokinesis failure (49). Consistent with this, tetraploid cells
are more sensitive to Aurora B inhibition (50). Moreover, overex-
pression of Aurora B has been correlated with poor prognosis in a
large number of cancers, including breast, ovarian, lung, nasopha-
ryngeal, and hepatocellular carcinomas (51–55). This evidence
has led to the development of small molecule inhibitors designed
to interfere with the ATP-binding pocket of Aurora kinases that
are currently in clinical trials for the treatment of various cancer
pathologies (5, 56). Aurora B inhibitors have the ability to silence
the spindle assembly checkpoint causing premature mitotic exit
and consequent chromosomemis-segregation, cytokinesis failure,
and nuclear fragmentation. All these defects ultimately lead to
cell death, and this antiproliferative effect could potentially affect
cancer cells that rely on Aurora B overexpression more than
normal cells. However, in the long term, Aurora B inhibitors also
interfere with the division of normal cells and indeed clinical
toxicity profiles ofAurora inhibitors indicated frequent side effects
such as myelosuppression, febrile neutropenia, and gastrointesti-
nal problems (nausea, diarrhea, and mucositis), some of which
have been directly attributed to Aurora B inhibition (5, 56). Fur-
thermore, ATP-binding competitors are often not very selective
and can inhibit the activity of other kinases. Thus, there is a need
to develop alternative, more selective, and less toxic approaches to
inhibit Aurora B activity.
There is evidence that targeting mitotic exit without perturbing
spindle assembly could potentially be a more effective cancer
treatment (57). In addition, low levels of cytokinesis failure do
not seem to affect the shape and size of proliferative tissues in
invertebrate animal models. For example, actively proliferating
tissues such as brains and imaginal disks (i.e., the tissues that give
rise to the adult fly) of larvae carrying strongmutant combinations
of the Drosophila CIT-K homologue are highly polyploid (8N or
more), misshapen, and smaller than their wild-type counterparts.
By contrast, the same tissues of larvae carrying weaker allelic
combinations are mostly tetraploid and normal in shape and size
(58). These results indicate that, at least in Drosophila, organs can
tolerate the presence of a considerable number of tetraploid cells
and thus one single event of cytokinesis failure does not appear
to significantly interfere with tissue development and function,
whereas multiple cytokinesis failures lead to cell death and impair
tissue development. Therefore, it is conceivable that inhibition
of cytokinesis could selectively affect the proliferation of very
actively dividing cells. There is also another motive to hypothesize
that cytokinesis failure could selectively eliminate cancer cells.
It is well established that many carcinomas present numerical
chromosomal abnormalities (aneuploidy and/or polyploidy) and
instability (59, 60). Therefore, provoking cytokinesis failure in
these already chromosomally abnormal cancer cells could very
rapidly increase their genomic content above a threshold compat-
ible with cell viability. Together, these data indicate that targeting
the cytokinetic functions of the CPC could be a valid alternative
strategy for antiproliferative cancer therapy. Clearly, inhibitors of
Aurora B kinase activity cannot be used to impair CPC functions
specifically during cytokinesis. However, the use of small peptides
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interfering with protein–protein interactions is emerging as a
valid alternative pharmacological approach and peptides able to
interfere with the interaction between INCENP and Aurora B
have already been successfully used to impair CPC activity (61).
Therefore, small peptides designed to impair CPC binding to
its cytokinesis partners – such as KIF20A, CIT-K, and CHMP4
proteins – could be used to specifically inhibit this complex during
cytokinesis and offer an alternative strategy for the development
of highly targeted and potentially less toxic anticancer therapies.
CONCLUDING REMARKS
Considerable progresses have been made in the last years to
understand themultiple roles of Aurora B and the CPC during the
rapid and highly coordinated process of cytokinesis. These studies
have indicated that the CPC plays important functions in every
step of this process, from the initial determination of the cleavage
plane to the final abscission of the two daughter cells. They have
also determined that the CPC controls the proper segregation
of the genomic material not only in early mitosis by controlling
kinetochore–microtubule attachments but also later in cytokinesis
by delaying abscission in the presence of lagging chromosomes at
the cleavage site. These findings suggest that the CPC probably
deserves the appellative of “guardian of genome segregation” for
its key role in preventing aneuploidy and CIN. However, impor-
tant questions still remain open. Do Aurora B and other kinases,
such as Plk1 and CIT-K, share common substrates during cytoki-
nesis? How is Aurora B function coordinated with that of other
kinases to cooperatively regulate the function of their various
substrates during cytokinesis? Elucidating these mechanisms will
keep scientist in the field busy for many years to come.
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